Abstract: A computing device is provided having at least one processor (104) operative to facilitate motion correction in a medical image file (102). The at least one processor (104) is configured to generate at least one unified frame file (110) based on motion image data (204), depth map data (206) corresponding to the motion image data, and region of interest data (200). Further, at least one corrected image file derived from the medical image file (102) is generated by performing the motion correction based on the at least one unified frame file (110) using the processor (104). Subsequently, the at least one corrected image file is outputted for display to one or more display devices (122).

Abstract: Disclosed herein are compositions for assessing peptidoglycan biosynthesis in bacteria, for identifying bacteria, and for screening for bacterial cell wall-acting and/or cell wall-disrupting agents via modified D-amino acids and methods of use thereof. Also disclosed are live bacteria having one or more modified D-amino acids as described herein incorporated into peptidoglycan of a bacterial cell wall.

Abstract: Genetically modified mice characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease are provided wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p,R47H (Trem2p) operably linked to a promoter, such that the mouse expresses human APOE4p and mouse Trem2p. Methods ace provided for screening for a compound for use in the treatment of Alzheimer's disease using such genetically modified mice.

Abstract: Methods are provided for the isolation, expansion, enrichment, and transplantation of endothelial stem cells from blood vessels and induced pluripotent stem cells via the use of ABCG2 cell surface marker. The ability of the endothelial stem cells to expand in vitro and be subsequently implanted in vivo to generate new blood vessels provides a therapeutic hope for patients with numerous cardiovascular disorders (peripheral arterial disease, critical limb ischemia, ischemic retinopathies, acute ischemic injury to kidney, and myocardial infarction) where the lack of sufficient blood vessel forming ability in the patient limits their regenerative capacity.

Abstract: Small molecule compounds derived from ?-sulfophenylacetic amide (SPAA) are provided as novel sulfonic acid based pTyr mimetics. These compounds effectively inhibit a variety of protein tyrosine phosphatases (PTPs), such as mPTPA, mPTPB, LMWPTP, and Laforin. Use of these compounds as pharmaceutical agents for treating diseases associated with abnormal protein tyrosine phosphatase activity is also provided.

Abstract: Methods for treating various cancers by administering one or more compounds that target the dimeric protein survivin are disclosed. Pharmaceutical compositions containing such compounds are also disclosed, along with general methods of identifying anti-cancer compounds that target oncogenic dimeric proteins. Exemplary compounds that can be used in the disclosed methods of treatment and pharmaceutical compositions have the chemical structure.

Abstract: The present disclosure provides compositions and methods for the treatment or prophylaxis of a perfusion disorder, such as ischemia and/or reperfusion injury, in a subject's organ, tissue or extremity by preserving or improving endothelial function, reducing vascular injury, and/or promoting vascular repair. The disclosed compositions comprise endothelial colony-forming cells or a serum-free composition comprising chemically defined media conditioned by endothelial colony-forming cells.

Abstract: A system and methods utilizing electrical stimulation to achieve a desired therapeutic effect are provided. In one aspect, a method for controlling nerve activity in a subject is provided. The method includes receiving input indicating a desired therapeutic effect for at least one neural structure of a subject, and selecting, based on the input received, an electrical stimulation configured to achieve the desired therapeutic effect. The method also includes controlling a sympathetic nerve activity in the subject by delivering the electrical stimulation using electrodes positioned proximate to nerves innervating the subject's skin.

Abstract: The invention provides a fusion protein comprising an antigen binding domain linked to a bacteriophage decoration (Dec) protein along with a polynucleotide comprising the nucleic acid sequence of the fusion protein and a vector comprising the polynucleotide. Additionally, the invention provides a composition comprising the fusion protein and a virus-like particle (VLP), and a method of treating a disease in a mammal comprising administering a therapeutically effective amount of the composition to the mammal. The invention also provides a method of vaccinating against a disease comprising administering a composition comprising the fusion protein and a VLP encapsulating a protein.

Abstract: Small molecule compounds derived from ?-sulfophenylacetic amide (SPAA) are provided as novel sulfonic acid based pTyr mimetics. These compounds effectively inhibit a variety of protein tyrosine phosphatases (PTPs), such as mPTPA, mPTPB, LMWPTP, and Laforin. Use of these compounds as pharmaceutical agents for treating diseases associated with abnormal protein tyrosine phosphatase activity is also provided.

Abstract: A hybrid ion mobility spectrometer includes a single-pass drift tube having an ion inlet and an ion outlet, a multiple-pass drift tube having an ion inlet and an ion outlet each coupled to the single pass drift tube between the ion inlet and the ion outlet thereof, and at least one ion steering channel controllable to selectively pass ions traveling through the single-pass drift tube into the multiple-pass drift tube via the ion inlet of the multiple-pass drift tube and to selectively pass ions traveling through the multiple-pass drift tube into the single-pass drift tube via the ion outlet of the multiple-pass drift tube. The single-pass drift tube separates in time ions traveling therethrough according to a first function of ion mobility, and the multiple-pass drift tube separates in time ions traveling one or more times therethrough according to the first or a second function of ion mobility.

Abstract: The present disclosure provides a mass spectrometry cartridge and methods of use thereof.

Abstract: A method for computing patient-specific hemodynamics. The method includes receiving three dimensional imaging data of a patent, extracting anatomical data from the three dimensional imaging data, calculating velocity and pressure fields corresponding to the extracted anatomical data, and calculating displacement and velocity of extracted solid particles corresponding to the anatomical data. The anatomical data comprises an anatomical boundary.

Abstract: System and methods for monitoring and/or controlling nerve activity in a subject are provided. In one embodiment, a system includes electrodes configured to be placed proximate to a subject's skin, and a signal detector configured to detect electrical signals using the electrodes. The system also includes a signal processor configured to receive the electrical signals from the signal detector, and apply a filter to the received electrical signals to generate filtered signals, the filter configured to attenuate at least signals having frequencies corresponding to heart muscle activity during a heartbeat. The signal processor is also configured to identify a skin nerve activity using the filtered signals, estimate a sympathetic nerve activity using the identified skin nerve activity, and further to generate a report indicative of the estimated sympathetic nerve activity. In some aspects, the system further includes a signal generator to deliver the electrical stimulation to the subject's skin.

Abstract: An identifier for a conduit includes a first tag having a body with a first aperture formed therein for receiving the conduit and a first identifying feature, and a second tag having a body with a second aperture formed therein for receiving the conduit and a second identifying feature that matches the first identifying feature. The first tag is attached to the conduit adjacent one end, the second tag is attached to the conduit adjacent another end, and the ends are identified as ends of the same conduit by the matching first and second identifying features.

Abstract: Described herein is the identification of cGMP-specific phosphodiesterase upregulation in cystic kidney diseases. Also described is the use of cGMP-specific phosphodiesterase inhibitors for preventing the progression and/or treatment of cystic kidney diseases. Other aspects described provide medicaments for preventing the progression and/or treating cystic kidney diseases, and methods of diagnosing cystic kidney disease.

Abstract: The present invention provides methods for diagnosing a patient with emphysema, COPD of lung injury caused by tobacco use by detecting the levels of EMAP II in a sample. Disclosed herein are the hypervariable regions for a rat monoclonal antibody that binds to a form of EMAP II. This disclosure also includes a polypeptide sequence included in EMAP II that is the target for the binding of the antibody to its target protein. This epitope serves as the basis for a humanized antibody that can be used to treat patients that suffer from pathologies that exhibit elevated levels of EMAP II expression.

Abstract: A system and method for monitoring nerve activity in a subject. The system includes a plurality of electrodes placed in proximity to skin of the subject, an amplifier electrically connected to the electrodes and configured to generate a plurality of amplified signals corresponding to electrical signals received from the subject through the electrodes, and a signal processor. The signal processor applies a high-pass filter to the amplified signals to generate filtered signals from the amplified signals, identifies autonomic nerve activity in the plurality of filtered signals; and generates an output signal corresponding to the filtered signals. The high-pass filter attenuates a plurality of the amplified signals having frequencies that correspond to heart muscle activity during a heartbeat.

Abstract: Systems comprising a processor in electrical communication with a tangible, non-transitory memory that, in response to an execution by the processor, cause the processor to measure a relative biological effectiveness of a beam on a region of a human body, and a beam applicator in electrical communication with the processor, wherein a characteristic of the beam can be adjusted based on the measured relative biological effectiveness are disclosed. Methods of treatment comprising measuring, by a processor capable of detecting potential biological hot spots, a relative biological effectiveness of a beam on a region of a human body, designing a beam therapy treatment plan based on the measured relative biological effectiveness, and applying a beam to a patient with a region in need of beam therapy with a beam applicator in electrical communication with the processor capable of detecting potential biological hot spots are also disclosed.

Abstract: The present disclosure relates to methods of using cannabinoid CB2 receptor agonist compositions to suppress pain (e.g., neuropathic pain), opioid tolerance, and/or opioid-induced physical dependence in a subject.